


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound of Use of the compounds of the formula I

in which

5



- X denotes CH or N,
R¹ denotes H, A, Hal, (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms, CF₃, NO₂, CN, C(NH)NOH or OCF₃,
R² denotes (CH₂)_nHet, (CH₂)_nAr, cycloalkyl having 3 to 7 C atoms or CF₃,
R³, R⁴ denote H, (CH₂)_nCO₂R⁵, (CH₂)_nCOHet, (CH₂)_nCON(R⁵)₂,
(CH₂)_nCOO(CH₂)_nHet (CH₂)_nCOO(CH₂)_nAr, CHO, (CH₂)_nOR⁵,
(CH₂)_nHet, (CH₂)_nN(R⁵)₂, CH=N-OA, CH₂CH=N-OA, (CH₂)_nNHOA,
(CH₂)_nN(R⁵)Het, (CH₂)_nCH=N-Het, (CH₂)_nOCOR⁵ (CH₂)_nCOOR⁵,
(CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂CH₂OCF₃,
(CH₂)_nN(R⁵)C(R⁵)HCOOR⁵ (CH₂)_nN(R⁵)C(R⁵)HCOOR⁵,
(CH₂)_nN(R⁵)CH₂COHet, (CH₂)_nN(R⁵)CH₂Het,
(CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)CH₂COOR⁵
(CH₂)_nN(R⁵)CH₂CH₂N(R⁵)CH₂COOR⁵, (CH₂)_nN(R⁵)CH₂CH₂OR⁵,
(CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCOOR⁵ CH=CHCOOR⁵,
CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵
CH=CHCH₂OR⁵, CH=CHCH₂Het, (CH₂)_nN(R⁵)Ar,
(CH₂)_nN(COOR⁵)COOR⁵ (CH₂)_nN(COOR⁵)COOR⁵,
(CH₂)_nN(CONH₂)COOR⁵ (CH₂)_nN(CONH₂)COOR⁵,
(CH₂)_nN(CONH₂)CONH₂, (CH₂)_nN(CH₂COOR⁵)COOR⁵ (CH₂)_nN(CH₂

OOCOR^5 , $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^5$

$(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{OOCOR}^5$, $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$,

$(\text{CH}_2)_n\text{CHR}^5\text{COR}^5$, $(\text{CH}_2)_n\text{CHR}^5\text{COOR}^5$, $(\text{CH}_2)_n\text{CHR}^5\text{OOCOR}^5$, or

$(\text{CH}_2)_n\text{CHR}^5\text{CH}_2\text{OR}^5$, $(\text{CH}_2)_n\text{CHR}^5\text{CH}_2\text{OR}^5$,

where in each case one of the radicals R^3 or R^4 has the meaning H,

R^5 denotes H or A

A denotes straight-chain or branched alkyl or cycloalkyl having 2 to 4 C atoms, having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

Het preferably denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR^5 , OR^5 , OCOR^5 , OOCOR^5 , COOR^5 , COOR^5 , $\text{CON}(\text{R}^5)_2$, CN, NO_2 , NH_2 , NHCOR^5 , CF_3 or SO_2CH_3 , SO_2CH_3 ,

n denotes 0, 1, 2, 3, 4 or 5, and

Hal denotes F, Cl, Br or I,

or a salt, solvate, enantiomer or racemate thereof

~~and salts and solvates, enantiomers and racemates thereof for the preparation of a medicament for the treatment and prophylaxis of diseases which can be influenced by the binding of the compounds of the formula I to 5-HT receptors.~~

2. (Currently Amended) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having~~ A method according to claim 1, wherein the compound of formula I has a 5-HT receptor-antagonistic action.

3. (Currently Amended) ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament having~~ A method according to claim 1, wherein the compound of formula I has a 5-HT_{2A} receptor-antagonistic action.

4. (Currently Amended) A method according to claim 1, wherein the disease is ~~Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the prophylaxis and/or treatment of psychoses, a neurological disorder disorders, amyotrophic lateral sclerosis, an eating disorder, disorders, such as bulimia, anorexia nervosa, of premenstrual syndrome and/or for positively influencing or obsessive-compulsive disorder (OCD).~~

5. (Currently Amended) A method ~~Use of the compounds of the formula I according to claim 1, in which R¹ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.~~

6. (Currently Amended) A method ~~Use of the compounds of the formula I according to claim 1, in which R³ denotes (CH₂)_nCO₂R⁵, (CH₂)_nCO-Het, CHO, CH₂OR⁵, (CH₂)_n-Het, (CH₂)_nN(R⁵)₂, or CH=N-OA, (CH₂)_nN(R⁵)Het, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het or (CH₂)_nN(R⁵)Ar.~~

7. (Currently Amended) A method ~~Use of the compounds of the formula I according to claim 1, in which R⁴ denotes H.~~

8. (Currently Amended) A method ~~Use of the compounds of the formula I according to claim 1, in which R² denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinoliny, isoquinoliny, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.~~

9. (Currently Amended) ~~A method Use of the compounds of the formula I according to claim 1, in which X has the meaning CH.~~


10. (Cancelled)

11. (New) A method according to claim 1, wherein the compound of formula I is
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1 -yl)amine;
4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;
4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;
1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;
1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;
1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;
N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;
2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino]ethanol;
[1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine;
2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino]ethanol;
1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;
1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;
1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or
[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine;
or a salt or solvate thereof.

12. (New) A method according to claim 1, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating

disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

13. (New) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound of formula I in which



X denotes CH or N,
 R^1 denotes H, A, Hal, $(CH_2)_n$ Het, $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms, CF_3 , NO_2 , CN, $C(NH)NOH$ or OCF_3 ,
 R^2 denotes $(CH_2)_n$ Het, $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms or CF_3 ,
 R^3, R^4 denote H, $(CH_2)_nCO_2R^5$, $(CH_2)_nCOHet$, $(CH_2)_nCON(R^5)_2$, $(CH_2)_nCOO(CH_2)_nHet$, CHO , $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $CH_2CH=N-OA$, $(CH_2)_nNHOA$, $(CH_2)_nN(R^5)Het$, $(CH_2)_nCH=N-Het$, $(CH_2)_nOCOR^5$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)HCOOR^5$, $(CH_2)_nN(R^5)CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$, $CH=CHCH_2Het$, $(CH_2)_nN(R^5)Ar$, $(CH_2)_nN(COOR^5)COOR^5$, $(CH_2)_nN(CONH_2)COOR^5$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^5)COOR^5$, $(CH_2)_nN(CH_2CONH_2)COOR^5$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^5COR^5$, $(CH_2)_nCHR^5COOR^5$, or $(CH_2)_nCHR^5CH_2OR^5$, where in each case one of the radicals R^3 or R^4 has the meaning H,
 R^5 denotes H or A

- A denotes straight-chain or branched alkyl having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,
- Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,
- Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR⁵, OCOR⁵, COOR⁵, CON(R⁵)₂, CN, NO₂, NH₂, NHCOR⁵, CF₃ or SO₂CH₃,
- n denotes 0, 1, 2, 3, 4 or 5, and
- Hal denotes F, Cl, Br or I,
or a salt thereof.

14. (New) A method according to claim 13, wherein the compound of formula I is

[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1-yl)amine;

4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;

4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;

1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;

1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;

1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;

1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;

N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;

2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino]ethanol;

[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine;

2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino]ethanol;

1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;
 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;
 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or
 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 - methylpyrrolidin-3-yl)amine;
 or a salt thereof.

15. (New) A method according to claim 13, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

16. (New) A method according to claim 14, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

17. (New) A method according to claim 1, in which
 R^1 denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,
 R^3 denotes $(CH_2)_nCO_2R^5$, $(CH_2)_nCO-Het$, CHO , CH_2OR^5 , $(CH_2)_n-Het$, $(CH_2)_nN(R^5)_2$, $CH=N-OA$, $(CH_2)_nN(R^5)Het$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$, $CH=CHCH_2Het$ or $(CH_2)_nN(R^5)Ar$,
 R^4 denotes H,
 R^2 denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or

5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and

X has the meaning CH.

18. (New) A method according to claim 13, in which

R¹ denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,

R³ denotes (CH₂)_nCO₂R⁵, (CH₂)_nCO-Het, CHO, CH₂OR⁵, (CH₂)_n-Het, (CH₂)_nN(R⁵)₂, CH=N-OA, (CH₂)_nN(R⁵)Het, (CH₂)_nN(R⁵)CH₂CH₂OR⁵, (CH₂)_nN(R⁵)CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂Het, (CH₂)_nN(R⁵)CH₂CH₂N(R⁵)₂, CH=CHCH₂NR⁵Het, CH=CHCH₂N(R⁵)₂, CH=CHCH₂OR⁵, CH=CHCH₂Het or (CH₂)_nN(R⁵)Ar,

R⁴ denotes H,

R² denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and

X has the meaning CH.

19. (New) A method according to claim 17, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

20. (New) A method according to claim 18, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).